Table 2b.
Baseline medication use in incident COPD and incident triple therapy cohort at start of follow-up.
| Medication categorya | Incident COPD cohort (N = 57,141) (%) | Incident triple therapy cohort (N = 8173) (%) | |
|---|---|---|---|
| Baseline medications at start of follow-up | LAMA | 1504 (2.6) | 7829 (95.8) |
| LABA | 99 (0.2) | 283 (3.5) | |
| LAMA + LABA | 60 (0.1) | 42 (0.5) | |
| ICS | 614 (1.1) | 617 (7.6) | |
| LABA + ICS | 1885 (3.3) | 7192 (88.0) | |
| SABA | 6594 (11.5) | 4923 (60.2) | |
| SAMA | 380 (0.7) | 164 (2.0) | |
| SABA + SAMA | 4266 (7.5) | 2708 (33.1) | |
| PDE-4 | 23 (0.04) | 93 (1.1) | |
| Methylxanthines | 883 (1.6) | 380 (4.7) | |
| COPD treatment combinations at start of follow-up | LABA + ICS | 1779 (3.1) | — |
| SABA + LAMA + LABA + ICS | 353 (0.6) | — | |
| SAMA + SABA + LAMA + LABA + ICS | 145 (0.3) | — | |
| SABA + LABA + ICS | 1101 (1.9) | — | |
| LABA + LAMA | 491 (0.9) | — | |
| COPD triple therapy combinations at start of follow-up | LABA/LAMA + ICS | 5 (0.01) | 36 (0.4) |
| LAMA + ICS/LABA | 1429 (2.5) | 7865 (96.2) | |
| LAMA + LABA + ICS | 45 (0.1) | 310 (3.8) | |
a
The medication categories are not mutually exclusive that is, the sum of total number of patients for all the medication categories could exceed 100%.
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; PDE-4, phosphodiesterase-4; SABA, short-acting beta agonist; SAMA, short-acting muscarinic antagonist.